# Pizarra — PT-pseudo_2cd88bcdf81c (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2cd88bcdf81c
Task: 1

Encounter: Urology - outpatient on 02 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 73-year-old male
  - PSA: 12.0 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.313 ng/mL²
  - PSA velocity: 2.57 ng/mL/yr
  - Prior PSA: 12.1 ng/mL
  - Prostate volume: 38.29 mL
  - Months since last PSA: 1
  - DRE findings: Not done (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8336016 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 12 ng/mL. PI-RADS 4. PSAD 0.31. Prostate volume 38 mL. csPCa 0.83.

Vitals: weight 74 kg, height 189 cm, BMI 20.7, BP 116/67 mmHg, HR 76 bpm. Smoking: Current smoker (25 pack-yr).

Chief complaint: Persistent elevation of prostate-specific antigen levels alongside a previously negative biopsy necessitates clinical reassessment.

History: Most recent prostate-specific antigen measurement stands at 12.0 ng/mL, recorded in January 2025. At seventy-three years of age, this divorced retired carpenter resides independently while sustaining an active routine that includes biweekly tennis matches. A substantial smoking history of 25 pack-yr remains current. Lower urinary tract symptoms are negligible, scoring merely 2 on the IPSS scale, with complete denial of hematuria or pelvic discomfort. Weekly alcohol intake averages twenty-six units, and recent visits covered standard dental care alongside endocrine screening for thyroid surveillance. Invasive interventions provoke marked anxiety, prompting a request for detailed explanations and extended consultation periods. Past medical background remains clear of comorbidities, with no prescribed medications and zero documented allergies.

Physical examination: DRE — texture: N/A, mobility: N/A, asymmetry: N/A. The examination was omitted entirely because of scheduling limitations and the patient’s explicit preference. General assessment shows stable parameters: blood pressure sits at 116/67 mmHg, heart rate rests at 76 bpm, and body mass index measures 20.7. Palpation of the abdomen yields a soft, non-tender response without detectable masses or organ enlargement.

Patient info: retired carpenter; Divorced; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 26 units / week; exercise Tennis 2x/week; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Dental — biannual check-up.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.83 +/- 0.14   (95% CI 0.48-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.12  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.07  (few labelled cases resemble this one)
  - 6.7 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=12.0, age=73.0, psad=0.313, vol=38.29, n_pmhx=0.0
  missing / not evaluable: dre_ord

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (2.57 ng/mL/yr), the specific trend of the PSA history, or the full laboratory panel results. These dynamic and detailed data points are crucial for assessing the aggressiveness suggested by the PI-RADS 4 and high csPCa probability.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy (0.83), but the data shows a prior negative biopsy. This creates a direct contradiction. The prior's high probability might be based on the PI-RADS 4 and high PSA, but the prior negative biopsy status is a strong piece of evidence that the prior failed to incorporate or weigh correctly. The wide error bar (0.14) suggests significant disagreement among the training set, meaning the prior's confidence is low.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report suggests a low-risk feature despite PI-RADS 4, it would decrease the likelihood of biopsy.
  <document> PSA history (trend) -> If the PSA velocity is low or declining, it would decrease the likelihood of biopsy.
  <document> laboratory results (full panel) -> If other markers suggest a benign profile, it would decrease the likelihood of biopsy.
  <document> previous GP / urology consultation notes -> If these notes contain specific clinical reasoning regarding the prior negative biopsy, it would refine the decision.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  RADIOLOGY CONSULTATION | 28 December 2024 | Multiparametric MRI of the Prostate
  Clinical Indication:
  Assessment for clinically significant malignancy following a PSA reading of 12.0 ng/mL and a previously negative biopsy.
  Findings:
  The glandular architecture occupies 38.29 mL of pelvic space. Within the right mid-gland peripheral zone, a discrete 14 x 11 mm region exhibits profound hypointensity on T2-weighted sequences, pressing against but not penetrating the prostatic capsule. Corresponding DWI reveals marked restriction with low ADC signal, indicative of high cellular density. Early focal enhancement appears on dynamic contrast sequences relative to adjacent tissue. Extracapsular extension and seminal vesicle invasion are absent. Suspicious lymphadenopathy is not visualized. The bladder and rectum remain unremarkable.
  Impression:
  Focal lesion in the right mid-prostate peripheral zone with imaging features highly suspicious for malignancy.
  PI-RADS 4.
  Prostate volume: 38.29 mL.
  PSA density: 0.313 ng/mL/mL.
  csPCa predicted probability 0.8336016.

  **PSA history**
  {"case_id": "PT-pseudo_2cd88bcdf81c", "psa_trend": [{"date": "Dec 2022", "val": 2.3}, {"date": "Dec 2023", "val": 5.3}, {"date": "Jan 2025", "val": 12.0}]}

  **laboratory results**
  {"case_id": "PT-pseudo_2cd88bcdf81c", "laboratory_results": [{"name": "PSA", "val": "12.0 ng/mL", "date": "09 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "2.04 ng/mL", "date": "09 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "17%", "date": "09 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "13.1 g/dL", "date": "09 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.6 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "249 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "100 umol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "09 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "14.0 nmol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "86 U/L", "date": "09 Dec 2024", "flag": ""}, {"name": "LDH", "val": "205 U/L", "date": "09 Dec 2024", "flag": ""}]}

  **previous GP / urology consultation notes**
  {"date": "07 May 2024", "author": "Dr. R. van den Berg (GP)", "text": "On 07 May 2024, the patient\u2019s clinical record noted a PSA increase to 12.1 ng/mL in December 2023, a marked jump from 8.9 ng/mL the prior year. A transrectal ultrasound-guided biopsy was subsequently performed, yielding a negative result for malignancy."}

NOT RETRIEVED
  get_family_history - Not called because the rule states this anamnesis is not part of the biopsy work-up.

WHAT THE EVIDENCE SUPPORTS
  findings that argue FOR sampling this patient now:
  Focal lesion in the right mid-prostate peripheral zone with imaging features highly suspicious for malignancy (PI-RADS 4).
  PSA velocity of 2.57 ng/mL/yr (from prior data).
  csPCa predicted probability 0.8336016.

  findings that argue AGAINST sampling this patient now:
  Prior biopsy was Negative.
  %Free PSA is 17%.

WHERE THIS LEANS
  The evidence strongly argues for sampling due to the high-risk MRI finding (PI-RADS 4) and the rising PSA velocity, which contradicts the prior negative biopsy result. This leans toward a strong recommendation for biopsy.

[Sections actually revealed in this consultation: psa_trend, laboratory_results, previous_notes, radiology_report. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the imaging findings are highly suspicious (PI-RADS 4) and the PSA velocity is rising (2.57 ng/mL/yr), which contradicts the prior negative biopsy. The decision is driven by the PI-RADS 4 score and the rising PSA velocity, which were marked as decisive factors. The statistical prior suggested biopsy, and the retrieved evidence strongly supports this action.

Variables that carried weight: bx=decisive, age=noted, psa=important, vol=noted, psad=important, pirads=decisive
Sections revealed: psa_trend, laboratory_results, previous_notes, radiology_report
